| Dr Michael Perl, AUD | |
|
2999 Princeton Pike Ste 2, Lawrenceville, NJ 08648-3261 | |
| (609) 403-8840 | |
| Not Available |
| Full Name | Dr Michael Perl |
|---|---|
| Gender | Male |
| Speciality | Qualified Audiologist |
| Experience | 5 Years |
| Location | 2999 Princeton Pike Ste 2, Lawrenceville, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578110367 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 41YA00105700 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ent And Allergy Associates Llp | 0749193662 | 368 |
News Archive
Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.
Higher blood pressure during exercise and delayed blood pressure recovery after exercise are associated with a higher risk of hypertension, preclinical and clinical cardiovascular disease and death among middle-aged to older adults.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
People who have a history of self-harm are more than three times as likely to die prematurely as the general population, and not just from the obvious causes, with deaths due to natural causes at least two times greater than anticipated and the risk also much higher for individuals living in socially deprived areas, according to a UK study published Online First in The Lancet.
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
› Verified 5 days ago
| Provider Name | Ent And Allergy Associates Llp |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376598326 PECOS PAC ID: 0749193662 Enrollment ID: O20041122001007 |
News Archive
Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.
Higher blood pressure during exercise and delayed blood pressure recovery after exercise are associated with a higher risk of hypertension, preclinical and clinical cardiovascular disease and death among middle-aged to older adults.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
People who have a history of self-harm are more than three times as likely to die prematurely as the general population, and not just from the obvious causes, with deaths due to natural causes at least two times greater than anticipated and the risk also much higher for individuals living in socially deprived areas, according to a UK study published Online First in The Lancet.
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
› Verified 5 days ago
| Provider Name | Princeton Eye & Ear Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1902185945 PECOS PAC ID: 4587802996 Enrollment ID: O20130524000180 |
News Archive
Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.
Higher blood pressure during exercise and delayed blood pressure recovery after exercise are associated with a higher risk of hypertension, preclinical and clinical cardiovascular disease and death among middle-aged to older adults.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
People who have a history of self-harm are more than three times as likely to die prematurely as the general population, and not just from the obvious causes, with deaths due to natural causes at least two times greater than anticipated and the risk also much higher for individuals living in socially deprived areas, according to a UK study published Online First in The Lancet.
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Perl, AUD 2999 Princeton Pike Ste 2, Lawrenceville, NJ 08648-3261 Ph: (609) 403-8840 | Dr Michael Perl, AUD 2999 Princeton Pike Ste 2, Lawrenceville, NJ 08648-3261 Ph: (609) 403-8840 |
News Archive
Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.
Higher blood pressure during exercise and delayed blood pressure recovery after exercise are associated with a higher risk of hypertension, preclinical and clinical cardiovascular disease and death among middle-aged to older adults.
Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir.
People who have a history of self-harm are more than three times as likely to die prematurely as the general population, and not just from the obvious causes, with deaths due to natural causes at least two times greater than anticipated and the risk also much higher for individuals living in socially deprived areas, according to a UK study published Online First in The Lancet.
In findings that should finally put to rest a decade of controversy in the field of neurobiology, a team at The Scripps Research Institute has found decisive evidence that a specific neurotransmitter system-the endocannabinoid system-is active in a brain region known to play a key role in the processing of memory, emotional reactions, and addiction formation. The new study also shows that this system can dampen the effects of alcohol, suggesting an avenue for the development of drugs to combat alcohol addiction.
› Verified 5 days ago
Dr. James Ross Dublin, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 2999 Princeton Pike Ste 2, Lawrenceville, NJ 08648 Phone: 609-583-4339 | |
Dr. Theodore Leroy Johnson, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 177 Franklin Corner Rd, Ste. 1b, Lawrenceville, NJ 08648 Phone: 609-895-1666 | |
Tanya L Arbogast, SC.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3100 Princeton Pike, Building 4, Suite A, Lawrenceville, NJ 08648 Phone: 609-439-4353 | |
Caitlin Ervin, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2999 Princeton Pike, Lawrenceville, NJ 08648 Phone: 609-915-9416 Fax: 609-403-8852 | |
Yasmin Battat, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 134 Franklin Corner Rd, Ste 104, Lawrenceville, NJ 08648 Phone: 609-896-5870 Fax: 609-896-5871 | |
Dr. Michael Rude, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3100 Princeton Pike Ste A, Lawrenceville, NJ 08648 Phone: 609-439-4353 |